MAFEIP is a web-based tool whose purpose is to estimate the health and economic outcomes of a large variety of social and technological innovations. From the EIP on AHA perspective, MAFEIP represents the key instrument to estimate the impact of EIP on AHA interventions.
MAFEIP enables early impact assessments of an innovative process in the health and care sector. Using this tool can help decision-makers to take informed decisions about the future design of this innovative process or about its deployment on a larger scale (this is the “decision to invest”).
MAFEIP can also help, at a later stage of the innovation development, to assess precisely its value for citizens and other stakeholders (this is the “decision to buy”).
The potential users of the MAFEIP tool are stakeholders in the health and care sectors who are willing to deploy innovative practices to improve quality of care, better accessibility or more efficient use of resources.
A renewed version of the MAFEIP tool (MAFEIP 2.0) was released at the end of 2017. Several improvements and new functionalities are based upon the results of the MAFEIP study, carried out by Open Evidence and empirica.
The launch of the new tool and the enlargement of the MAFEIP users’ community have been supported by the restyling of the MAFEIP website. The site has been redesigned, enriched with additional services oriented to the specific needs of the different stakeholders accessing the site, and made easier to use.
During the EIP on AHA Conference of Partners 2018, a specific session titled “MAFEIP 2.0: Decision to Invest, Decision to Buy” was dedicated to showcasing the new tool and illustrating how it can support evidence-based decision making in health and social care intervention design. The session was co-chaired by Arnaud Senn, EC, DG CNECT, and by Prof Francisco Lupiáñez-Villanueva, Open Evidence Co-Founder and Director. The attendees learned from the panellists about their experiences as users of the MAFEIP tool and understood how MAFEIP has been beneficial to them.
In June 2018, a call was launched to invite organisations to test the new version of the tool. A total of 21 proposals were received. The MAFEIP team is now holding meetings with some of the interested organisations to help them use MAFEIP to evaluate their interventions. This activity is supported by the coordination and support action, We4AHA.
MAFEIP 2.0 has already been used to develop a new use case, the cost-effectiveness analysis of Do CHANGE. This project had the aim of empowering individuals with high blood pressure, ischemic heart disease or heart failure chronic conditions with tools and services to optimally monitor and manage their real-time health condition and disease. The use case has been developed by Badalona Serveis Assistencials in conjunction with Smart Homes.
Open Evidence is committed to disseminate the work, and increase the outreach, of the MAFEIP community through different channels so as to expand engagement with and use of the MAFEIP tool. The MAFEIP Users’ Community has been growing since February 2017, grouping an increasing number of organisations across Europe and reaching almost 200 members. The goal is to continue expanding the community throughout 2019.
As a result of the June 2018 call, it is expected that several new MAFEIP use cases will be developed until summer 2019. Once ready, the use cases will be published on the MAFEIP website.
The MAFEIP support team at Open Evidence continues to provide technical and operational support to all those organisations that wish to use MAFEIP to assess impact and cost-effectiveness of the digital health interventions they are implementing or planning to adopt.
The MAFEIP team is leveraging the breadth of their members’ existing international networks and the multiple connections established through European funded projects to promote the use of MAFEIP across Europe.
Regular reports of MAFEIP outputs will be released, illustrating the impact on the EIP on AHA activities.
The MAFEIP tool is open to any interested organisation or individual. So, if you are willing and interested to try the tool, do not hesitate to ask for a username at email@example.com